This week in drug discovery (3-7 June)
News round-up for 3-7 June by DDW Senior Digital Content Editor Diana Spencer.
With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluding this week, the headline news has all focused on breakthrough cancer research shared at the event.
The top stories:
New drug represents a ‘remarkable advancement’ in lung cancer
New data show that an unprecedented 60% of patients with advanced lung cancer given Lorbrena (lorlatinib) remain alive without disease progression after five years.
Immunotherapy prior to surgery a ‘game-changer’ for bowel cancer
Phase II trial results have shown the superiority of immunotherapy pembrolizumab over chemotherapy when given before bowel cancer surgery.
Cancer vaccine shows sustained improvement in survival rates
Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma.
Ozempic reduces risk of 13 types of cancer
Patients taking semaglutide (the active ingredient in Wegovy and Ozempic) were 19% less likely to develop 13 obesity-related cancers, according to new data.
As well as key findings with regards to lorlatinib for lung cancer, epcoritamab in follicular lymphoma, and pembrolizumab for bowel cancer, there were other significant study results revealed at ASCO.
